Comparison of efficacy and safety of Paliperidone Extended-Release Tablets and Olanzapine Tablets in the treatment of schizophrenia in children and adolescents
LI Duo-cong, CHEN Hai-feng
Department of Psychiatry,Ji′an Third People′s Hospital of Jiangxi Province,Ji′an 343000,China
Abstract：Objective To investigate the efficacy and safety of Paliperidone Extended-Release Tablets and Olanzapine Tablets in the treatment of schizophrenia in children and adolescents.Methods A total of 100 patients with schizophrenia who were admitted to our hospital from April 2013 to April 2016 were selected as subjects,and randomly divided into the Paliperidone Extended-Release Tablets group (group P,n=50) and Olanzapine Tablets group (group A,n=48).Both groups were treated for 12 weeks.PANSS scores were compared between the two groups before treatment and 1,2,4,6,8,10 and 12 weeks after treatment.The incidence of adverse reactions were also compared between the two groups.Results The patients in the group P was effective earlier than that in group A,and the difference was statistically significant (P<0.05).When medication was extended to 12 weeks after treatment,the efficacy of the two groups was compared,and difference was not statistically significant (P>0.05).The incidence of narcolepsy,abnormal liver function,abnormal blood lipid and weight gain were lower in group P than those in group A,the incidence of akathisia was higher than group A,and the differences were statistically significant (P<0.05).Conclusion Paliperidone Extended-Release Tablets and Olanzapine Tablets has similar efficacy in the treatment of schizophrenia in children and adolescents,but Paliperidone Extended-Release Tablets has less side effects than Olanzapine Tablets,and it works faster.
李多聪, 陈海峰. 帕利哌酮缓释片和奥氮平片治疗儿童青少年精神分裂症的效果和安全性比较[J]. 中国当代医药, 2017, 24(24): 75-77.
LI Duo-cong, CHEN Hai-feng. Comparison of efficacy and safety of Paliperidone Extended-Release Tablets and Olanzapine Tablets in the treatment of schizophrenia in children and adolescents. 中国当代医药, 2017, 24(24): 75-77.
Gareri P,Segura-García C,Manfredi VGL, et al .Use of atypical antipsychotics in the elderly：a clinical review[J]. Clin Interv Aging,2014,9：1363.
[5]
Komossa K,Rummel Kluge C,Schwarz S, et al. Risperdone versus other atypical antipsychotics for schizophrenia[J].cochrane Database Syst Rev,2011,8（1）：968-970.
Reading R.Mental health of young people：a global public-health challenge[J].Lancet,2007,369（9569）：1302.
[8]
郝伟,于欣.精神病学（第7版）[M].北京：人民卫生出版社,2013：24.
[9]
Pani L,Marchese G.Expected clinical benefits of paliperidone extended-relsasd formulation when compared with risperidone immediate-release expert opin[J].Drug Deliv,2009,6（3）：319-331.
[10]
Fowler JA,Bettnger TL,Argo TR.Paliperidone extended-release tab lets for the acute and maintenance of schizophrenia[J].Clin Ther,2008,30（2）：231-248.
[11]
Gray JA,Roth BL.The pipeline and future of drug development in schizophrenia[J].Mol Psychiatry,2007,12（10）：904-922.
[12]
Turgay A,Binder C,Snyder R, et al .Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs[J].Pediatrics,2002,110（3）：e34.
京公网安备 11010502046607号